CFAH PROSTATE CANCER TRANSLATIONAL RESEARCH GROUP – VHIO – Vall d'Hebron Institute of Oncology

PRECLINICAL & TRANSLATIONAL RESEARCH
Prostate Cancer Translational Research Group

JOAQUIN MATEO
Principal Investigator
Biosketch

Over the last decade, we have witnessed a revolution in the treatment of advanced prostate cancer.  However, it is still a lethal disease, and further therapeutic strategies are needed. Our group’s mission is to improve advanced prostate cancer management through investigating  tumor response and resistance mechanisms and by correlating clinical and molecular data to movetowards more precise patient care.

Our research model follows a bench-to-bedside-and-back approach. We have set up a platform for acquiring longitudinal samples from advanced prostate cancer patients, both tumor tissue as well as liquid biopsies that can be used to investigate the evolving features of the disease, but also to generate patient-derived laboratory models of advanced prostate cancer that we can leverage to investigate new therapeutic strategies in the bench. Moreover, the launch of investigator-initiated clinical trials is central to our research strategy, as a platform for correlative studies that can optimize the drug development pathway for prostate cancer patients. At present, we are the central laboratory for two academic multi-center clinical trials, as well as serving as national repository for the IRONMAN registry, an  international effort to build a comprehensive bank of clinical data and biospecimens from mPC patients.

We aim to  integrate our workin molecular biology, genomics, transcriptomics, computational sciences and clinical data into developing precision medicine strategies for prostate cancer patients. To that end, our team is composed of biomedical scientists with expertise in cancer biology, genomics and transcriptomics, bioinformatics and liquid biopsies, together with medical oncologists and clinical data scientists.

One of our main  research objectives is to understand how prostate cancers adapt to exposure to systemic therapies, particularly androgen-targeting agents, with a particular interest in 1) the cell cycle and DNA damage response regulation and 2) the emergence of quiescent and senescent phenotypes that can drive drug resistance. By studying in-vitro and in-vivo models, including patient-derived xenografts from patients participating in our clinical studies, we try to understand how to target emergent phenotypes through drug combinations. These studies are currently funded by the Spanish Ministry of Health, Fundación FERO and Fundación AECC as well as through collaborations with biopharmaceutical companies.

Moreover, we aim to pursue molecular characterization of advanced prostate cancer, focusing on how cancerevolves in a heterogeneous manner as it becomes resistant to different treatments. Thus, we have set up a genomics and transcriptomics platform in the lab capable of pursuing DNA and RNA profiling from patient biopsies. We are developing novel liquid biopsies assays that will enable us to study the disease through longitudinal samples. Moreover, our computational scientists study the changes in the genomics profile of the disease over time and at different stages of the disease. These studies are currently funded by the US DoD CDMRP, the Spanish Ministry of Health, CRIS Cancer Foundation, Fundación AECC; Fundación FERO and La Caixa Foundation.

Last, we acknowledge that well-annotated clinical data is crucial to understand the potential relevance of molecular data; hence, our team maintains databases collecting outcome data for all patients who donate samples to our studies, to pursue later correlative analysis. Moreover, we are engaged in different team-science collaborative efforts to create  more relevant resources in order to advance the field of prostate cancer care.
In sum, we aim for our research to integrate different modalities of data generated in the lab that can lead to designing therapeutic interventions that make a difference for prostate cancer patients.


RESEARCH LINES

  • To investigate correlations between patient molecular profiling and clinical outcome that can guide more precise prostate cancer treatment strategies.
  • To study how prostate cancers adapt to therapy, with a focus on targeting emerging vulnerabilities to delay disease recurrence.
  • To study tumor heterogeneity in response to therapy in preclinical and patient-derived xenograft models, as well as by interrogating patient biopsies.
  • To investigate the optimal drug combinations targeting the DNA damage repair system and AR signaling.
  • To develop new liquid biopsy tools that can monitor tumor evolution.
  • To apply computational pipelines towards investigating genomic signatures in prostate cancer.
  • Development of academic clinical trials to validate in the clinic our laboratory results, and leveraging patient biopsies for correlative studies.

PROJECTS

  1. Defining the Landscape and Clinical Relevance of ATM Defects in Lethal Prostate Cancer – Prostate Cancer Foundation
  2. Caracterización del impacto funcional de mutaciones en genes de la reparación del DNA en pacientes con cáncer de próstata – Fundación Española de Oncología Médica
  3. Clinical Qualification of DNA Repair Defects as Biomarkers in Metastatic Prostate Cancer Using Integrated Genomics and Tissue-Based Functional Assays – Department of Defense (DoD)
  4. Perfiles moleculares de cáncer de próstata asociados a defectos de la reparación del ADN para el desarrollo de estrategias de medicina personalizada – Instituto de Salud Carlos III
  5. Co-targeting androgen receptor signalling and DNA damage repair for precision therapy – European Commission
  6. Novel approaches to liquid biopsy in prostate cancer to inform precision medicine – Fundación FERO
  7. Leveraging the AR-DDR interaction in de-novo metastatic prostate cancer towards precision combination therapies with PARP inhibitors (AECC)
  8. PROSTATE CANCER GENOMIC EVOLUTION AND SIGNATURES OF DNA DAMAGE REPAIR DEFICIENCIES (CRIS Cancer Foundation)

TEAM

  • Principal Investigator
    • Joaquin Mateo
  • Senior Researcher
    • Nicolas Herranz
  • Post-Doctoral Fellows
    • Luisa Delgado
    • Irene Casanova
  • Clinical Research Fellow
    • Pablo Cresta
  • Technicians
    • Teresa Casals
    • Sarai Cordoba
    • Natalia Castro
    • Lucila González
    • Olaia Baylo
  • PhD Student
    • Sara Arce
    • Julian Brandariz
  • Master students
    • Arnau Solé
    • Víctor Esquefa
  • Bioinformatician
    • David Aguilar
  • Clinical Data Curator
    • Vacant

Most relevant scientific publications

  • Casanova-Salas I, Athie A, Boutros PC, Del Re M, Miyamoto DT, Pienta KJ, Posadas EM, Sowalsky AG, Stenzl A, Wyatt AW, Mateo J. Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. Eur Urol. 2021 Jun;79(6):762-771. doi: 10.1016/j.eururo.2020.12.037. Epub 2021 Jan 7
  • Neeb A, Herranz N, Arce-Gallego S, Miranda S, Buroni L, Yuan W, Athie A, Casals T, Carmichael J, Rodrigues DN, Gurel B, Rescigno P, Rekowski J, Welti J, Riisnaes R, Gil V, Ning J, Wagner V, Casanova-Salas I, Cordoba S, Castro N, Fenor de la Maza MD, Seed G, Chandran K, Ferreira A, Figueiredo I, Bertan C, Bianchini D, Aversa C, Paschalis A, Gonzalez M, Morales- Barrera R, Suarez C, Carles J, Swain A, Sharp A, Gil J, Serra V, Lord C, Carreira S, Mateo J, de Bono JS. Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. Eur Urol. 2021 Feb;79(2):200-211.
  • Carreira [MOU1] S, Porta N, Arce-Gallego S, Seed G…….Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial. Cancer Discovery 2021
  • Westphalen B, Fine AD, Andre F….Mateo J CCR 2021 [MOU2]
  • Rescigno P, Gurel B, Pereira R, Crespo M, Rekowski J, Rediti M, Barrero M, Mateo J, Bianchini D, Messina C, Fenor de la Maza MD, Chandran K, Carmichael J, Guo C, Paschalis A, Sharp A, Seed G, Figueiredo I, Lambros M, Miranda S, Ferreira A, Bertan C, Riisnaes R, Porta N, Yuan W, Carreira S, de Bono JS. Characterizing CDK12-Mutated Prostate Cancers. Clin Cancer Res. 2021 Jan 15;27(2):566-574. doi: 10.1158/1078-0432.CCR-20-2371. Epub 2020 Sep 28
  • Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20
  • Abida, Cyrta, Heller…… PNAS 2019 [MOU3]
  • de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.PMID: 32343890
  • Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, Syndikus I, Ralph C, Jain S, Varughese M, Parikh O, Crabb S, Robinson A, McLaren D, Birtle A, Tanguay J, Miranda S, Figueiredo I, Seed G, Bertan C, Flohr P, Ebbs B, Rescigno P, Fowler G, Ferreira A, Riisnaes R, Pereira R, Curcean A, Chandler R, Clarke M, Gurel B, Crespo M, Nava Rodrigues D, Sandhu S, Espinasse A, Chatfield P, Tunariu N, Yuan W, Hall E, Carreira S, de Bono JS. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020 Jan;21(1):162-174.
  • Mateo J, Cheng HH, Beltran H, DollingD, XuW, Pritchard CC, MossopH, RescignoP, Perez-LopezR, SailerV, Kolinsky M, BalasopoulouA, BertanC, NanusDM, TagawaST, ThorneH, MontgomeryB, CarreiraS, Shahneen Sandhu S, RubinMA, Nelson PS, de BonoClinical outcome of prostate cancer patients with germline DNA repair mutations: follow-up from an international study. Eur Orol. 2018 doi:10.1016/j.euro.2018.01.010
  • Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L. A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol.2018 Sep 1;29(9):1895-1902.
  • Mateo J,* Carreira S*, Sandhu S*, Miranda S, Mossop H, Perez-Lopez R, et al DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. 2015. N Engl J Med 373(18):1697-1708.
  • Goodall J*, Mateo J*, Yuan W, Mossop H, Porta N, Miranda S et al. Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discov. 2017 Sep;7(9):1006-1017

All publications

  • Mateo J, Seed G. Bertan C, Rescigno P, Dolling D, Figueiredo I, et al. (2019)Genomics of lethal prostate cancer at diagnosis and castration-resistance. J Clin Inv., ePub ahead of print, Dec.; DOI 10.1172/JCI132031.
  • Mateo J, Porta N, Bianchini D, McGovern U, Elliot T, Jones R et al. (2019) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, ePub ahead of print, Dec 2019; DOI: 10.1016/S1470-2045(19)30684-9.
  • Athie A, Arce S, Gonzalez M, Morales R, Suarez C, Casals T, Hernandez G, Carles J, Mateo J. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. Curr Onc Rep. 2019. 1007/s11912-019-0790-6
  • Abida, Wassim; Cyrta, Joanna; Heller, Glenn; Prandi, Davide; Armenia, Joshua; Coleman, Ilsa; Cieslik, Marcin; Benelli, Matteo; Robinson, Dan; Van Allen, Eliezer M; Sboner, Andrea; Fedrizzi, Tarcisio; Mosquera, Juan Miguel; Robinson, Brian D; De Sarkar, Navonil; Kunju, Lakshmi P; Tomlins, Scott; Wu, Yi Mi; Nava Rodrigues, Daniel; Loda, Massimo; Gopalan, Anuradha; Reuter, Victor E; Pritchard, Colin C; MATEO, JOAQUIN; Bianchini, Diletta; Miranda, Susana; Carreira, Suzanne; Rescigno, Pasquale; Filipenko, Julie; Vinson, Jacob; Montgomery, Robert B; Beltran, Himisha; Heath, Elisabeth I; Scher, Howard I; Kantoff, Philip W; Taplin, Mary-Ellen; Schultz, Nikolaus; deBono, Johann S; Demichelis, Francesca; Nelson, Peter S; Rubin, Mark A; Chinnaiyan, Arul M; Sawyers, Charles L. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Nat Acad Sci. 2019. 1073/pnas.1902651116
  • Zafeiriou, Zafeiris; Bianchini, Diletta; Chandler, Robert; Rescigno, Pasquale; Yuan, Wei; Carreira, Suzanne; Barrero, Maialen; Petremolo, Antonella; Miranda, Susana; Riisnaes, Ruth; Rodrigues, Daniel Nava; Gurel, Bora; Sumanasuriya, Semini; Paschalis, Alec; Sharp, Adam; MATEO, JOAQUIN; Tunariu, Nina; Chinnaiyan, Arul M; Pritchard, Colin C; Kelly, Kevin; de Bono, Johann S. Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. European Urology, 2019. 10.1016/j.eururo.2018.09.048
  • Nava Rodrigues, Daniel; Casiraghi, Nicola; Romanel, Alessandro; Crespo, Mateus; Miranda, Susana; Rescigno, Pasquale; Figueiredo, Ines; Riisnaes, Ruth; Carreira, Suzanne; Sumanasuriya, Semini; Gasperini, Paola; Sharp, Adam; MATEO, JOAQUIN; Makay, Alan; McNair, Christopher; Schiewer, Matthew; Knudsen, Karen; Boysen, Gunther; Demichelis, Francesca; de Bono, Johann S. Clin Cancer Res, 2019. 10.1158/1078-0432.CCR-18-2068
  • MATEO, JOAQUIN; Fizazi, Karim; Gillessen, Silke; Heidenreich, Axel; PEREZ LOPEZ, RAQUEL; Oyen, Wim J G; Shore, Neal; Smith, Matthew; Sweeney, Christopher; Tombal, Bertrand; Tomlins, Scott A; de Bono, Johann S. Managing Nonmetastatic Castration-resistant Prostate Cancer. European Urology, 2019. 10.1016/j.eururo.2018.07.035
  • MATEO, JOAQUIN; Lord, C J; SERRA, VIOLETA; Tutt, A; BALMAÑA, JUDITH; CASTROVIEJO, CRISTINA; CRUZ, CRISTINA; OAKNIN, ANA; Kaye, S B; de Bono, J S. A decade of clinical development of PARP inhibitors in perspective. Ann Onc, 2019. 10.1093/annonc/mdz192
  • Sharp, Adam; Welti, Jon C; Lambros, Maryou B K; Dolling, David; Rodrigues, Daniel Nava; Pope, Lorna; Aversa, Caterina; Figueiredo, Ines; Fraser, Jennifer; Ahmad, Zai; Lu, Changxue; Rescigno, Pasquale; Kolinsky, Michael; Bertan, Claudia; Seed, George; Riisnaes, Ruth; Miranda, Susana; Crespo, Mateus; Pereira, Rita; Ferreira, Ana; Fowler, Gemma; Ebbs, Berni; Flohr, Penny; Neeb, Antje; Bianchini, Diletta; Petremolo, Antonella; Sumanasuriya, Semini; Paschalis, Alec; MATEO, JOAQUIN; Tunariu, Nina; Yuan, Wei; Carreira, Suzanne; Plymate, Stephen R; Luo, Jun; de Bono, Johann S. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. European Urology. 10.1016/j.eururo.2019.04.006
  • Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard C, et al. Clinical outcome of prostate cancer patients with germline DNA repair mutations: follow-up from an international study. Eur Urol. 2018 doi:10.1016/j.euro.2018.01.010

    Nava-Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros M, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer, J Clin Inv. 2018; 128-11, pp.5185-5185.

  • Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol., August 2018, 29-9: 1895-1902.
  • Boysen G, Nava Rodrigues D, Rescigno P, Seed G, Dolling DI, Riisnaes R, Crespo M, et al. SPOP mutated/ CHD1 deleted lethal prostate cancer and abiraterone sensitivity. Clin Can Res. 2018; 24-22: 5585-5593.
  • Mateo J, Carles J. 2018. Towards a New Classification for Metastatic Prostate Cancer, Eur Urol.
  • Lorente, D, Olmos D, Mateo J et al. 2018. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Ann Oncol. 29-7, pp.1554-1560.
  • Joaquin Mateo , Gopinath Ganji , Charlotte Lemech , Howard A. Burris , Sae-Won Han , Karen Swales , Shaun Decordova , Maurice P DeYoung , Deborah A Smith , Shanker Kalyana-Sundaram , Jiuhua Wu , Monica Motwani , Rakesh Kumar , Jerry M Tolson , Sun Young Rha , Hyun Cheol Chung , Joseph Paul Eder , Sunil Sharma, Yung-Jue Bang , Jeffrey R. Infante ,Li Yan, Johann de Bono, Hendrik-Tobias Arkenau. A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2017 Oct 1;23(19):5981-5992.
  • Seed G, Yuan W, Mateo J, Carreira S, Bertan C, Lambros M, Boysen G, Ferraldeschi R, Miranda S, Figueiredo I, Riisnaes R, Crespo M, Rodrigues DN, Talevich E, Robinson DR, Kunju LP, Wu YM, Lonigro R, Sandhu S, Chinnayan A, de Bono JS. Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. Clin Cancer Res. 2017 Oct 15;23(20):6070-6077.
  • Goodall J*, Mateo J*, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Nava Rodrigues D, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS. Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discovery. 2017 Apr 27 [Epub ahead of print] DOI: 10.1158/2159-8290.CD-17-0261
  • Massard C, Mateo J, Loriot Y, Pezaro C, Albiges L, Mehra N, Varga A, Bianchini D, Ryan CJ, Petrylak DP, Attard G, Shen L, Fizazi K, de Bono J. : Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of Oncology. 2017 Jan 1;28(1):90-95
  • Pritchard C*, Mateo J*, Walsh M*, de Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin M, Robinson D, Lonigro R, Hussein M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, Aldubayan S, Han C, Beightol M, Morissey C, Nghiem B, Cheng H, Montgomery B, Walsh T, Casadei S, Vijai J, Scher H, Sawyers C, Schultz N, Kantoff P, Solit D, Robson M, Van Allen E, Offit K, de Bono JS, Nelson P. (on behalf of the SU2C-PCF Prostate Cancer Dream Team] Inherited DNA repair gene mutations in men with metastatic prostate cancer. N Engl J Med, 2016; 375(5)443-45.
  • Mateo J,* Carreira S*, Sandhu S*, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A’Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. 2015. N Engl J Med 373(18):1697-1708.
  • Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro R, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng F, Tomlins SA, Conney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu, EY, Mostaghel EA, Cheng HH, Mulcahy H, True L, Plymate SR, Dyinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson B, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PA, Garraway LA, Sawyers CL, Chinnaiyan AM. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215–28.
  • Perez-Lopez R, Mateo J, Mossop H, Blackledge MD, Collins DJ, Rata M, Morgan VA, Macdonald A, Sandhu S, Lorente D, Rescigno P, Zafeiriou Z, Bianchini D, Porta N, Hall E, Leach MO, de Bono JS, Koh DM, Tunariu N. Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology. 2017 Apr;283(1):168-177
  • Perez-Lopez R, Lorente D, Blackledge MD, Collins DJ, Mateo J, Bianchini D, Omlin A, Zivi A, Leach MO, de Bono JS, Koh DM, Tunariu N. Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. Radiology 2016; 280(1):151-160.
  • Ferraldeschi R, Nava D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, Mateo J, Altavilla A, Sideris S, Bianchini D, Girst E, Thway K, Perez-Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, de Bono JS. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. European Urology 2015;67(4):795–802.
  • Mateo J, Olmos D, Dumez H, Poondru S, Samberg N, Barr S, Van Tornout JM, Jie F, Sandhu S, Tan DS, Moreno V, LoRusso PM, Kaye SB, Schoffski P. A first-in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. Br J Cancer 2016, 114, 889-896
  • Mateo J, Moreno V, Gupta A, Kaye SB, Dean E, Middleton MR, Friedlander M, Gourley C, Plummer R, Rustin G, Sessa C, Leunen K, Ledermann J, Swaisland H, Fielding A, Bannister W, Nicum S, Molife LR. An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor Olaparib. Target Oncol. 2016 Jun;11(3):401-15
  • McDaniel AS, Ferraldeschi R, Krupa R, Landers M, Graf R, Louw J, Jendrisak A, Bales N, Marrinucci D, Zafeiriou Z, Flohr P, Sideris S, Crespo M, Figueiredo I, Mateo J, de Bono JS, Dittamore R, Tomlins SA, Attard G. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. BJU Int. 2016 Aug (EPub)
  • Rescigno P, Lorente D, Bianchini D, Ferraldeschi R, Kolinsky MP, Sideris S, Zafeiriou Z, Sumanasuriya S, Smith AD, Mehra N, Jayaram A, Perez-Lopez R, Mateo J, Parker C, Dearnaley DP, Tunariu N, Reid A, Attard G, de Bono JS. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. European Urology. 2016 Nov;70(5):724-731.
  • Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M, Danila DC, Flohr P, Crespo M, Figueiredo I, Miranda S, Baeten K, Molina A, Kheoh T, McCormack R, Terstappen LW, Scher HI, de Bono JS. Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. European Urology. 2016; 70*6)985-992.
  • Lorente D, Omlin A, Zafeiriou Z, Nava-Rodrigues D, Pérez-López R, Pezaro C, Mehra N, Sheridan E, Figueiredo I, Riisnaes R, Miranda S, Crespo M, Flohr P, Mateo J, Altavilla A, Ferraldeschi R, Bianchini D, Attard G, Tunariu N, de Bono J. Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. Clin Genitourin Cancer. 2016 Dec;14(6):485-493
  • Frenel J-S, Carreira S, Goodall J, Roda-Perez D, Perez-Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Smith A, Leux C, Garcia-Murillas I, Ferraldeschi R, Lorente D, Mateo J, Ong M, Yap TA, Banerji U, Gasi D, Turner N, Attard G, de Bono JS. Serial Next Generation Sequencing of Circulating Cell Free DNA Evaluating Tumour Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res 2015; 21(20):4586-96.
  • Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, Bahl A, Shen L, Su Z, Sartor O, de Bono JS. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015 Apr;26(4):750-5
  • Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, Mateo J, Altavilla A, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, de Bono J. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol. 2015 Apr;67(4):795-802
  • Wilbaux M, Tod M, De Bono J, Lorente D, Mateo J, Freyer G, You B, Hénin E. A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer. CPT Pharmacometrics Syst Pharmacol. 2015 May;4(5):277-85
  • Mateo J, Berlin J, de Bono JS, Cohen RB, Keedy V, Mugundu G, Zhang L, Abbattista A, Davis C, Gallo Stampino C, Borghaei H. A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemother Pharmacol 2014, 74(5):1039-46.
    Ong M, Carreira S, Goodall J, Mateo J, Figueiredo I, Rodrigues DN, Perkins G, Seed G, Yap TA, Attard G, de Bono JS. Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. Br J Cancer 2014;111(5):828-36.
  • Ravi P, Mateo J, Lorente D, Zafeiriou Z, Altavilla A, Ferraldeschi R, Sideris S, Grist E, Smith A, Wong S, Bianchinni D, Attard G, de Bono JS. External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone. European Urology 2014;66(1):8–11.
  • Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol. 2013 Feb;229(3):422-9.
  • Mateo J, Carreira S, de Bono JS. Acquiring evidence for precision prostate cancer care. Annals Oncology. 2017 Apr 13. (Epub ahead of print)
  • Mateo J, Sharp A, de Bono JS. Investigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care? European Urology. 2017 Feb 20.
  • Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS. DNA Repair in Prostate Cancer: Biology and Clinical Implications. European Urology. 2017 Mar;71(3):417-425.
  • Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G. Sequencing agents in metastatic prostate cancer. Lancet Oncology 2015 Jun;16(6):e279-92.
  • Lorente D, Mateo J, Zafeiriou Z, Smith AD, Sandhu S, Ferraldeschi R, de Bono JS. Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Nat Rev Urol. 2015 Jan;12(1):37-47.
  • Mateo J, Gerlinger M, Rodrigues DN, de Bono JS. The promise of circulating tumor cell analysis in cancer management Genome Biol. 2014 Aug 30;15(8):448.
  • Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS. Appraising iniparib, the PARP inhibitor that never was–what must we learn? Nat Rev Clin Oncol. 2013 Dec;10(12):688-96.